menu search

APLS / Apellis Pharmaceuticals, Inc. (APLS) Q1 2023 Earnings Call Transcript

Apellis Pharmaceuticals, Inc. (APLS) Q1 2023 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Meredith Kaya - Senior Vice President, Investor Relations and Strategic Finance Dr. Cedric Francois - Co-Founder and CEO Adam Townsend - Chief Commercial Officer Dr. Caroline Baumal - Chief Medical Officer Tim Sullivan - Chief Financial Officer Conference Call Participants Madhu Kumar - Goldman Sachs Jon Miller - Evercore Tazeen Ahmad - BofA Anupam Rama - JPMorgan Colleen Kusy - Baird Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Phil Nadeau - TD Cowen Justin Kim - Oppenheimer Derek Archila - Wells Fargo Eliana Merle - UBS Annabel Samimy - Stifel Joseph Stringer - Needham & Company Douglas Tsao - H.C. Wainwright Operator Good day and thank you for standing-by. Read More
Posted: May 6 2023, 10:56
Author Name: Seeking Alpha
Views: 082223

APLS News  

Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales

By Zacks Investment Research
November 2, 2023

Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales

Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in t more_horizontal

Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 1, 2023

Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants Cedric Francois - Co-Fo more_horizontal

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates

By Zacks Investment Research
November 1, 2023

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.84. This co more_horizontal

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

By GlobeNewsWire
October 25, 2023

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

WALTHAM, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conferen more_horizontal

New Strong Buy Stocks for October 24th

By Zacks Investment Research
October 24, 2023

New Strong Buy Stocks for October 24th

MFA, GFF, OPI, APLS and GRPN have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2023. more_horizontal

Pharma Stock Upgraded on Eye Disorder Drug Sales

By Schaeffers Research
October 6, 2023

Pharma Stock Upgraded on Eye Disorder Drug Sales

Apellis Pharmaceuticals Inc (NASDAQ:APLS) stock is enjoying a boost today after an upgrade from J.P. more_horizontal

Trending stocks October 6, 2023: E.l.f. Beauty, Apellis Pharma, AutoZone:

By Yahoo Finance
October 6, 2023

Trending stocks October 6, 2023: E.l.f. Beauty, Apellis Pharma, AutoZone:

Stocks take in the morning's September jobs report data. e.l.f. Beauty (ELF) shares tick up this morning following an upgrade to "Buy" from Jefferies more_horizontal

Why Shares of Apellis Pharmaceuticals Were Down Wednesday

By The Motley Fool
September 27, 2023

Why Shares of Apellis Pharmaceuticals Were Down Wednesday

Apellis just got a J-code for reimbursement for its lead therapy from CMS. The company saw revenue climb 473% year over year in the second quarter. more_horizontal


Search within

Pages Search Results: